ClinicalTrials.gg
CompletedNCT04830215Updated Feb 2, 2024Results posted

Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

A Phase 4 interventional study of Brexpiprazole in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
122
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
14th of 24
122 · median 189
Started
2021
the only one that year
Phase 4
3 of 24
1 open now
Registered
22nd of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 14th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 4, and was the 22nd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in participants with Major Depressive Disorder (MDD) with a current depressive episode.

Read the detailed description

This is a phase 4, multicenter, open-label, flexible dose trial designed to assess the effects of brexpiprazole (flexible dose; 0.5 to 2 milligrams [mg], once daily [QD]) as adjunctive therapy to antidepressant therapy (ADT) on life engagement in participants with MDD. This trial is being conducted in line with the Canadian Product Monograph.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • MDD
  • Depression
  • Brexpiprazole
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants (outpatients) between the regional age of majority (18 or 19 years of age) to 65 years of age, inclusive, at the time of .
  • Primary diagnosis of MDD and in a current non-psychotic major depressive episode (MDE) as defined by , 5th Edition (DSM-5) criteria, who have been outpatients for at least 4 weeks, and have an inadequate response, per investigator judgment, to 1 or 2 adequate treatments of ADTs in their current MDE, including current ADT.
  • Participants with a Patient Health Questionnaire 9-item scale (PHQ-9) ≥ 15 at the screening and baseline visits, if separate.

Exclusion criteria

Exclusion Criteria:

  • Participants currently or previously treated with brexpiprazole including participants who received brexpiprazole in any prior clinical trial.
  • Participants with a concurrent diagnosis of the following will be excluded:

    • Schizophrenia or schizoaffective disorder
    • Bipolar I or bipolar II disorder
    • Post-traumatic stress disorder
    • Dementia
    • Eating disorder
    • Borderline personality disorder
    • Antisocial personality disorder
  • Participants with a suicidality score of 3 based on Inventory of Depressive Symptomatology Self-Report (IDS-SR) suicidality item 18 or participants who, in the opinion of the investigator, presents a serious risk of suicide.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Other
    Brexpiprazole

    Participants received brexpiprazole as a flexible dose; 0.5 mg to 2 mg, orally (PO), QD, and continued on the stable dose of ADT up to 8 weeks.

    Drug: Brexpiprazole

Interventions

  • Oral brexpiprazole tablets as adjunctive therapy to ADT

    Also known as: OPC-34712

06

What researchers measure

Primary outcomes

  1. Change From Baseline in IDS-SR-10 Engagement

    The IDS-SR-10 engagement consist of selected 10 item scores, including the following 10 items (clinician-selected): item 8 - Response of your mood to good or desired events, item 15 - Concentration/decision making, item 16 - View of myself, item 17 - View of my future, item 19 - General interest, item 20 - Energy level, item 21 - Capacity for pleasure or enjoyment (excluding sex), item 22 - Interest in sex (interest rated, not activity), item 23 - Feeling slowed down, and item 29- Interpersonal sensitivity. All the 10 items are rated on a 0 (best) to 3 (worst) scale. IDS-SR-10 engagement total score ranges from 0 (best) to 30 (worst). A negative change from baseline indicated improvement. Least square (LS) mean was calculated using a mixed model repeated measure (MMRM) analysis.

    Time frame: Baseline to Week 8

  2. Change From Baseline in IDS-SR Total Score

    The IDS-SR is a 30-item self-report measure that was used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorder (MDD). Each item on the IDS-SR scale was rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. IDS-SR total score is the sum of ratings of 28 item scores with the total score ranging from 0 (best) to 84 (worst). Under item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. A negative change from baseline indicated improvement. LS mean was calculated using a MMRM analysis.

    Time frame: Baseline to Week 8

07

Results

Posted Feb 2, 2024

Participant flow

Participants took part in this study at 15 investigative sites in Canada from 01 April 2021 to 27 May 2022.

Participant flow — Overall Study
MilestoneBrexpiprazole
Started122
Efficacy analysis set120
Safety analysis set120
Completed111
Not completed11
Withdrew: Adverse event6
Withdrew: Failure to meet continuation criteria1
Withdrew: Withdrawal by subject3
Withdrew: Protocol deviation1

Outcome measures

PrimaryChange From Baseline in IDS-SR-10 Engagement

The IDS-SR-10 engagement consist of selected 10 item scores, including the following 10 items (clinician-selected): item 8 - Response of your mood to good or desired events, item 15 - Concentration/decision making, item 16 - View of myself, item 17 - View of my future, item 19 - General interest, item 20 - Energy level, item 21 - Capacity for pleasure or enjoyment (excluding sex), item 22 - Interest in sex (interest rated, not activity), item 23 - Feeling slowed down, and item 29- Interpersonal sensitivity. All the 10 items are rated on a 0 (best) to 3 (worst) scale. IDS-SR-10 engagement total score ranges from 0 (best) to 30 (worst). A negative change from baseline indicated improvement. Least square (LS) mean was calculated using a mixed model repeated measure (MMRM) analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in IDS-SR-10 Engagement
score on a scaleBrexpiprazole
Change From Baseline in IDS-SR-10 Engagement-8.11 ± 0.62
Statistical analysis
  • Brexpiprazole · MMRM · p = <0.0001 (MMRM included fixed effect terms for visit, baseline value, an interaction term of baseline value by visit, and trial center.)
PrimaryChange From Baseline in IDS-SR Total Score

The IDS-SR is a 30-item self-report measure that was used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorder (MDD). Each item on the IDS-SR scale was rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. IDS-SR total score is the sum of ratings of 28 item scores with the total score ranging from 0 (best) to 84 (worst). Under item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. A negative change from baseline indicated improvement. LS mean was calculated using a MMRM analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in IDS-SR Total Score
score on a scaleBrexpiprazole
Change From Baseline in IDS-SR Total Score-17.38 ± 1.36
Statistical analysis
  • Brexpiprazole · MMRM · p = <0.0001 (MMRM included fixed effect terms for visit, baseline value, an interaction term of baseline value by visit, and trial center.)

Adverse events

Collected over From first dose of study drug up to Week 8. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole0/120 (0%)0/120 (0%)45/120 (37.5%)
Most frequent other events
Most frequent other events
EventBrexpiprazole
FatigueGeneral disorders13/120
HeadacheNervous system disorders13/120
InsomniaPsychiatric disorders12/120
NauseaGastrointestinal disorders9/120
TremorNervous system disorders8/120
Weight increasedInvestigations7/120

Baseline characteristics

The Enrolled Analysis Set included all participants who had signed the informed consent form (ICF) for the trial and had enrolled into the open-label treatment phase.

Age, Continuous
Age, Continuous(years)Brexpiprazole
Mean43.0 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole
Female79
Male43
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brexpiprazole
Race — White111
Race — Black or African American1
Race — Asian7
Race — Other3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brexpiprazole
Ethnicity — Hispanic or Latino1
Ethnicity — Not Hispanic or Latino117
Ethnicity — Unknown3
Ethnicity — Other1
IDS-SR-10 Engagement
IDS-SR-10 Engagement(score on a scale)Brexpiprazole
Mean16.1 ± 4.7
IDS-SR Total Score
IDS-SR Total Score(score on a scale)Brexpiprazole
Mean41.3 ± 9.8
08

Study locations

1 site
  • Chatham-Kent Clinical Trials Research Centre
    Chatham, Ontario N7L 1C1, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in May 2022, 13 months.

Results were first posted in Feb 2024, 1 year 8 months after primary completion.

Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2021
First posted
Apr 5, 2021
StartActual
Apr 1, 2021
Primary completionActual
May 27, 2022
CompletionActual
May 27, 2022
Results first posted
Feb 2, 2024
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04830215
Responsible party
Sponsor
First posted
Apr 5, 2021
Start date
Apr 1, 2021
Primary completion
May 27, 2022
Completion
May 27, 2022
Results posted
Feb 2, 2024
Last update
Feb 2, 2024

Study contacts

Eva Kohegyi, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion